Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
235 hedge funds and large institutions have $306M invested in Sorrento Therapeutics, Inc. in 2022 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 89 increasing their positions, 37 reducing their positions, and 37 closing their positions.
283% more call options, than puts
Call options by funds: $14.4M | Put options by funds: $3.76M
141% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 37
11% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 37
0% more funds holding
Funds holding: 234 → 235 (+1)
29% less capital invested
Capital invested by funds: $433M → $306M (-$127M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$60.4M |
| 2 |
D.E. Shaw & Co
New York
|
+$15M |
| 3 |
Morgan Stanley
New York
|
+$7.38M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$5.17M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$10.2M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
-$1.74M |
| 3 |
Barclays
London,
United Kingdom
|
-$1.02M |
| 4 |
Citigroup
New York
|
-$1.02M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$982K |
SRNE Hedge Fund Activity: Q1 2022 in Review
235 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q1 2022, worth a combined $306M — down 29% from $433M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new SRNE positions and 37 closed out — a net gain of 4 holders — while 89 added to existing stakes and 37 trimmed.
The largest buyer was State Street, adding an estimated $60.4M. The largest seller was Sabby Management, exiting entirely with an estimated $10.2M sold.
- 235 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q1 2022, up from 234 in Q4 2021.
- Funds reported $306M of Sorrento Therapeutics, Inc. stock for Q1 2022, down 29% quarter-over-quarter.
- 41 funds opened new Sorrento Therapeutics, Inc. positions in Q1 2022 and 37 closed out, a net change of +4 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q1 2022 was State Street, an estimated $60.4M added.
- The largest Sorrento Therapeutics, Inc. seller in Q1 2022 was Sabby Management, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2022.